FFA
CRL icon

Fairfield Financial Advisors’s Charles River Laboratories CRL Stock Holding History

Fairfield Financial Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-432
Closed -$79.7K – 95
2024
Q4 		$79.7K Hold
432
– – 0.03% 94
2024
Q3 		$85.1K Sell
432
-160
-27% -$33.3K 0.03% 106
2024
Q2 		$122K Buy
+592
New +$134K 0.04% 87
2023
Q4 		$278K Sell
1,177
-458
-28% -$90.1K 0.11% 63
2023
Q3 		$320K Sell
1,635
-145
-8% -$29.8K 0.13% 49
2023
Q2 		$374K Sell
1,780
-1,391
-44% -$277K 0.15% 50
2023
Q1 		$628K Sell
3,171
-610
-16% -$138K 0.27% 43
2022
Q4 		$824K Sell
3,781
-1,067
-22% -$233K 0.38% 34
2022
Q3 		$954K Sell
4,848
-1,162
-19% -$251K 0.45% 32
2022
Q2 		$1.29M Sell
6,010
-5,039
-46% -$1.23M 0.59% 29
2022
Q1 		$3.14M Buy
+11,049
New +$3.41M 1.13% 24

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.4B AUM 13.97% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fairfield Financial Advisors's CRL Position: Q1 2025 in Review

Fairfield Financial Advisors sold out of Charles River Laboratories (CRL) in Q1 2025, closing a stake of 432 shares — an estimated $79.7K sold.

Fairfield Financial Advisors first reported a position in CRL in Q1 2022 and held it in 11 quarters. The position peaked at $3.14M in Q1 2022. 561 funds tracked by Wall St. Rank hold CRL as of Q1 2025.

  • Fairfield Financial Advisors reported no remaining Charles River Laboratories position as of Q1 2025 after selling out during the quarter.
  • Fairfield Financial Advisors sold 432 Charles River Laboratories shares in Q1 2025, an estimated $79.7K.
  • Fairfield Financial Advisors first reported a position in Charles River Laboratories in Q1 2022 and held it in 11 quarters.
  • Fairfield Financial Advisors's Charles River Laboratories position peaked at $3.14M in Q1 2022.
  • 561 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2025.

Based on Fairfield Financial Advisors's 13F filing for Q1 2025, filed 9 May 2025.